SCHEMBL2406751

SCHEMBL2406751

C[C@@H](NS(=O)(=O)c1ccc(C(F)(F)F)cc1)c1ccc(C(=O)NO)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP7 P09237 3/20 0.49
MMP1 P03956 3/20 0.49
MMP9 P14780 2/20 0.49
MMP3 P08254 2/20 0.49
MMP13 P45452 2/20 0.49
MMP2 P08253 1/20 0.49
MMP10 P09238 1/20 0.48
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
EEF2K O00418 3/20 0.43
HDAC8 Q9BY41 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2411724 0.84 MMP7 (0.46) MMP7MMP1MMP9MMP3MMP13
SCHEMBL2411726 0.84 MMP7 (0.46) MMP7MMP1MMP9MMP3MMP13
SCHEMBL2409572 0.84 HDAC1 (0.51) MMP7MMP1MMP9MMP3MMP13
SCHEMBL2413093 0.79 MMP7 (0.52) MMP7MMP1MMP9MMP3MMP13
SCHEMBL2412670 0.79 MMP7 (0.52) MMP7MMP1MMP9MMP3MMP13
SCHEMBL2405981 0.77 MMP1 (0.45) MMP7MMP1MMP9MMP3MMP13
SCHEMBL2404440 0.76 EPHX2 (0.49) HDAC8HDAC3HDAC6MAPTHTT
SCHEMBL6919178 0.75 HDAC3 (0.52) MMP7MMP1MMP9MMP3MMP13
SCHEMBL2407939 0.75 HDAC3 (0.44) HDAC3HDAC4HDAC1
SCHEMBL2406492 0.74 EEF2K (0.49) MMP7MMP1MMP9MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9227951-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-01-05 US disclosed
US-9227951-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-01-05 US disclosed
US-20140228416-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-14 US disclosed
US-20140228416-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-14 US disclosed
US-8546588-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-10-01 US disclosed
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC3 MMP7 871/4885MMP1 443/4885MMP9 887/4885
US-20140228416-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC3 MMP7 871/4885MMP1 443/4885MMP9 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.